Clinically approved nanoparticle-based medicines for lung cancer therapy
| Name | Active ingredient | Formulation | Clinical phase | First approval |
|---|---|---|---|---|
| Genexol-PM | PTX | Polymeric micelle | Approved | 2007 |
| Abraxane | PTX | Albumin | Approved | 2012 |
| Lipusu | PTX | Liposome | Approved | 2019 |
| AGEN1181 | αCTLA-4 | Phospholipid | I/II phase | 2020 |
| PEP02 | Irinotecan | Liposome | II phase | 2015 |
| DM-CHOC-PEN | DNA alkylator | Lipoid (chloroethyl-cyclohexyl-nitrosourea) | I/II phase | 2021 |
| NKTR-214 | IL-2 | PEG | I/II phase | 2022 |